Spyre Therapeutics, Inc. announced an accelerated timeline for its SPY003 (IL-23p19) program, with first-in-human dosing now expected in the first quarter of 2025. This represents a significant advancement in the company's pipeline for inflammatory bowel disease (IBD) treatments.
New preclinical data for SPY003 were presented at the United European Gastroenterology Week (UEGW) Congress on October 12, 2024. The data demonstrated robust preclinical activity, including comparable potency and a greater than three-fold extension in half-life in non-human primates relative to risankizumab.
Additionally, preclinical data on SPY003 in combination with SPY001 or SPY002 were presented, showing enhanced preclinical efficacy and pharmacodynamics. These findings support Spyre's strategy of developing both monotherapy and combination products with the potential to improve efficacy and convenience in IBD treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.